Efficacy and safety of fasiglifam (
            TAK
            ‐875), a
            G
            protein‐coupled receptor 40 agonist, in
            J
            apanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase
            III
            trial

K. Kaku; K. Enya; R. Nakaya; T. Ohira; R. Matsuno

doi:10.1111/dom.12467

Efficacy and safety of fasiglifam ( TAK ‐875), a G protein‐coupled receptor 40 agonist, in J apanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12467 ◽

2015 ◽

Vol 17 (7) ◽

pp. 675-681 ◽

Cited By ~ 78

Author(s):

K. Kaku ◽

K. Enya ◽

R. Nakaya ◽

T. Ohira ◽

R. Matsuno

Keyword(s):

Type 2 Diabetes ◽

G Protein ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Diet And Exercise ◽

G Protein Coupled

Download Full-text

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12631 ◽

2016 ◽

Vol 18 (5) ◽

pp. 528-532 ◽

Cited By ~ 12

Author(s):

S. Hong ◽

C.-Y. Park ◽

K. A. Han ◽

C. H. Chung ◽

B. J. Ku ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2014.935764 ◽

2014 ◽

Vol 15 (11) ◽

pp. 1501-1515 ◽

Cited By ~ 78

Author(s):

Nobuya Inagaki ◽

Kazuoki Kondo ◽

Toru Yoshinari ◽

Nahoko Takahashi ◽

Yutaka Susuta ◽

...

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Diet And Exercise ◽

Phase Iii Study

Download Full-text

Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Journal of Diabetes Investigation ◽

10.1111/jdi.13389 ◽

2020 ◽

Author(s):

Linong Ji ◽

Jianhua Ma ◽

Weiping Lu ◽

Jingdong Liu ◽

Jiao’e Zeng ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Chinese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Diet And Exercise

Download Full-text

Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in K orean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12424 ◽

2015 ◽

Vol 17 (3) ◽

pp. 309-312 ◽

Cited By ~ 22

Author(s):

M. K. Kim ◽

E.‐J. Rhee ◽

K. A. Han ◽

A. C. Woo ◽

M.‐K. Lee ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

1089-P: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of HD-6277, a Potent and Selective G-Protein-Coupled Receptor 40 (GPR40) Agonist, in Patients with Type 2 Diabetes Mellitus

Diabetes ◽

10.2337/db20-1089-p ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 1089-P

Author(s):

KI-HWAN KIM ◽

HYE-JUNG YANG ◽

MYOUNGKI BAEK

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

G Protein ◽

Phase 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Study ◽

G Protein Coupled

Download Full-text

A randomized, double‐blind, placebo‐controlled, phase II clinical trial to investigate the efficacy and safety of oral DA‐1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise

Diabetes/Metabolism Research and Reviews ◽

10.1002/dmrr.2613 ◽

2014 ◽

Vol 31 (3) ◽

pp. 295-306 ◽

Cited By ~ 25

Author(s):

Chang Hee Jung ◽

Cheol‐Young Park ◽

Kyu‐Joeng Ahn ◽

Nan‐Hee Kim ◽

Hak‐Chul Jang ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Clinical Trial ◽

Type 2 Diabetes Mellitus ◽

Glycaemic Control ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Diet And Exercise

Download Full-text

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.13340 ◽

2018 ◽

Vol 20 (9) ◽

pp. 2121-2130 ◽

Cited By ~ 14

Author(s):

Yu Hong Chen ◽

Chien-Ning Huang ◽

Young Min Cho ◽

Pengfei Li ◽

Liqun Gu ◽

...

Keyword(s):

Type 2 Diabetes ◽

East Asian ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Active Comparator ◽

Asian Patients ◽

East Asian Patients

Download Full-text

Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials

Clinical Therapeutics ◽

10.1016/j.clinthera.2014.07.020 ◽

2014 ◽

Vol 36 (11) ◽

pp. 1595-1605 ◽

Cited By ~ 11

Author(s):

Rosemarie Lajara ◽

Richard Aguilar ◽

Uwe Hehnke ◽

Hans-Juergen Woerle ◽

Maximilian von Eynatten

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Pooled Data ◽

Phase Iii Trials

Download Full-text

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension

Diabetes Obesity and Metabolism ◽

10.1111/dom.12011 ◽

2012 ◽

Vol 14 (12) ◽

pp. 1145-1154 ◽

Cited By ~ 34

Author(s):

A. H. Barnett ◽

S. Patel ◽

R. Harper ◽

R. Toorawa ◽

S. Thiemann ◽

...

Keyword(s):

Type 2 Diabetes ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Diabetes Patients

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1146988.604098 ◽

2009 ◽

Author(s):

Frank Pessler

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Withdrawal Phase ◽

Systemic Onset

Download Full-text